# EDGAR Filing Document

**Accession Number:** 0001625101
**File Stem:** 0001437749-25-033348
**Filing Date:** 2025-11
**Character Count:** 23482
**Document Hash:** 49b222674f5fb00846477d96db0eb156
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-25-033348.hdr.sgml**: 20251105

**ACCESSION NUMBER**: 0001437749-25-033348

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20251105

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251105

**DATE AS OF CHANGE**: 20251105

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PULSE BIOSCIENCES, INC.
- **CENTRAL INDEX KEY:** 0001625101
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 465696597
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37744
- **FILM NUMBER:** 251454071

**BUSINESS ADDRESS:**
- **STREET 1:** 3957 POINT EDEN WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545
- **BUSINESS PHONE:** 510-906-4600

**MAIL ADDRESS:**
- **STREET 1:** 3957 POINT EDEN WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Pulse Biosciences, Inc.
- **DATE OF NAME CHANGE:** 20151210

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Electroblate, Inc.
- **DATE OF NAME CHANGE:** 20141113

?xml version='1.0' encoding='ASCII'? plse20250826_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM**8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **<u>November 5, 2025</u>**

---

| | | |
|:---|:---|:---|
| **Pulse Biosciences, Inc.** | **Pulse Biosciences, Inc.** | **Pulse Biosciences, Inc.** |
| (Exact Name of Registrant as Specified in Its Charter) | (Exact Name of Registrant as Specified in Its Charter) | (Exact Name of Registrant as Specified in Its Charter) |
| **Delaware** | **001-37744** | **46-5696597** |
| (State or Other Jurisdiction<br> of Incorporation) | (Commission<br> File Number) | (IRS Employer<br> Identification No.) |
| **601 Brickell Key Drive, Suite 1080** | **601 Brickell Key Drive, Suite 1080** | **601 Brickell Key Drive, Suite 1080** |
| **Miami,**Florida 33131** | **Miami,**Florida 33131** | **Miami,**Florida 33131** |
| (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) | (Address of Principal Executive Offices) (Zip Code) |
| **<u>**<u>510</u>**-**<u>906-4600</u>**</u>** | **<u>**<u>510</u>**-**<u>906-4600</u>**</u>** | **<u>**<u>510</u>**-**<u>906-4600</u>**</u>** |
| (Registrant's Telephone Number, Including Area Code) | (Registrant's Telephone Number, Including Area Code) | (Registrant's Telephone Number, Including Area Code) |

---

---

| |
|:---|
| **Not Applicable** |
| (Former Name or Former Address, If Changed Since Last Report) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
| Common stock, $0.001 par value per share | PLSE | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.**  |

---

On November 5, 2025, Pulse Biosciences, Inc. (the "Company") announced certain financial and operational results for the fiscal quarter ended September 30, 2025. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by this reference.

This information, as well as Exhibit 99.1, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits

---

| | |
|:---|:---|
| **<u>Exhibit</u>** <br> **<u>Number</u>** | **<u>Description</u>** |
| 99.1 | [Press Release issued by Pulse Biosciences, Inc. dated November 5, 2025 - Business Update and Financial Results](ex_857348.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **PULSE BIOSCIENCES, INC.** | **PULSE BIOSCIENCES, INC.** |
| Date: November 5, 2025 | By: | /s/ Jon Skinner |
|  |  | Jon Skinner |
|  |  | Chief Financial Officer<br> *(Principal Financial Officer)* |

---

## Exhibit 99.1

**Exhibit 99.1**

**Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results**

**HAYWARD, California. [Business Wire]** – November 5, 2025. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the third quarter ended September 30, 2025.

**Recent Business Highlights**

**Soft Tissue Ablation** 

● Initiated a multi-center clinical study, PRECISE-BTN, for the treatment of benign thyroid nodules (BTN) with the nPulse Vybrance percutaneous electrode system and have now enrolled 40% of the study subjects.

● Generated $86 thousand in revenue through commencement of the limited market release.

● Treated over 200 patients to date across the pilot program, the PRECISE-BTN Study, and initial commercial procedures.

**Surgical AF Ablation** 

● Received FDA IDE approval and enrolled the initial subject in the nPulse Cardiac Surgery System Study, NANOCLAMP AF, for the treatment of atrial fibrillation (AF), representing the first PFA study approved by FDA for a surgical cardiac ablation device in concomitant surgical procedures.

● Treated 44 patients to date and generated positive clinical outcomes, as indicated by follow up remapping procedures, as part of the nsPFA Cardiac Surgery System AF feasibility study in Europe.

● Late-Breaking data from the nPulse™ Cardiac Surgical System first-in-human feasibility study presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting highlighted that the electroanatomical mapping results for the first 24 patients treated show durable and consistent pulmonary vein isolation and posterior box isolation, each achieved safely with rapid ablation times.

**Endocardial Catheter AF Ablation** 

● Submitted FDA IDE application, including the pivotal study protocol, and plan to commence an IDE study in Q1 2026.

● Treated 150 total patients with the nsPFA 360° catheter to date as part of the multi-center, AF feasibility study in Europe.

"In each of our three market programs, we continue to accomplish the clinical and regulatory milestones required to deliver the benefits of nanosecond PFA to more patients and providers," said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. "We are advancing early market adoption for the nPulse Vybrance Percutaneous Electrode System, enrolling patients in the IDE pivotal study for the nPulse Cardiac Surgery System and progressing our IDE submission for our nPulse 360 Catheter, while we continue to treat patients in our two feasibility studies in Europe. The Pulse Biosciences team is executing our strategy to validate the safety, efficacy, and market-disrupting potential of our nPulse technology platform and we are very pleased with the patient outcomes and our early clinical results achieved to date."

**Third Quarter 2025 Financial Results**

Total revenue was $86 thousand for the third quarter of 2025, including both nPulse capital and Vybrance disposables sales.

Total GAAP costs and expenses, representing cost of product revenue, research and development, and selling, general, and administrative expenses, for the three months ended September 30, 2025, were $20.5 million, an increase of $6.8 million compared to $13.7 million in the prior year period. The increase was primarily driven by administrative expenses related to the expanding organization to support advancement of the nsPFA device clinical trials and commercialization, and non-cash stock-based compensation. Non-GAAP costs and expenses for the three months ended September 30, 2025, were $14.6 million, an increase of $4.2 million compared to $10.4 million in the prior year period.

GAAP net loss for the three months ended September 30, 2025 was ($19.4) million compared to ($12.7) million for the three months ended September 30, 2024. Non-GAAP net loss for the three months ended September 30, 2025 was ($13.5) million compared to ($9.4) million for the three months ended September 30, 2024.

------

Cash and cash equivalents totaled $95.2 million as of September 30, 2025, compared to $79.0 million as of September 30, 2024 and $106.3 million as of June 30, 2025. Cash used in operating activities in the third quarter of 2025 totaled $13.0 million, compared to $9.0 million used in the same period in the prior year, and $12.8 million used in the second quarter of 2025.

Reconciliations of GAAP to Non-GAAP cost and expenses and net loss have been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Financial Measures."

**Webcast and Conference Call Information**

Pulse Biosciences' management will host a conference call today, November 5, 2025, beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 7706791. A live and recorded webcast of the event will be available at https://investors.pulsebiosciences.com/.

**About Pulse Biosciences**<sup>®</sup>

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company's proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

**Non-GAAP Financial Measures**

In this press release, in order to supplement the Company's condensed consolidated financial statements presented in accordance with Generally Accepted Accounting Principles, or GAAP, management has disclosed certain non-GAAP financial measures for the statement of operations. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance. Company management uses these measurements as aids in monitoring the Company's ongoing financial performance from quarter to quarter, and year to year, on a regular basis and for financial and operational decision-making. Non-GAAP adjustments include stock-based compensation, depreciation and amortization, restructuring, severance, and a legal settlement. From time to time in the future, there may be other items that the Company may exclude if the Company believes that doing so is consistent with the goal of providing useful information to management and investors. The Company has provided a reconciliation of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. Investors are cautioned that there are a number of limitations associated with the use of non-GAAP financial measures as analytical tools. Investors are encouraged to review these reconciliations, and not to rely on any single financial measure to evaluate the Company's business.

Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies, which could reduce the usefulness of the Company's non-GAAP financial measures as tools for comparison. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Non-GAAP financial measures in this earnings release exclude non-cash expenses for stock-based compensation, depreciation and amortization, restructuring costs, severance expense, and legal settlement expenses.

------

**Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements concerning the effectiveness of the Company's nPulse technology to non-thermally clear cells while sparing adjacent noncellular tissue, statements concerning the potential market opportunities for the use of nsPFA to treat AF or benign thyroid nodules and whether these markets might grow in the future; statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device, such as the nPulse Cardiac Surgical System, statements concerning the Company's future clinical and regulatory initiatives anywhere in the world, such as whether the FDA will approve the Company's presently pending IDE submission, the Company's expectations, whether stated or implied, regarding whether the Company's nsPFA technology will become a disruptive, superior and durable treatment option for treating atrial fibrillation or any other medical condition, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences' current expectations, estimates, and projections regarding Pulse Biosciences' business, operations and other similar or related factors. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expects," "intends," "plans," "projects," "believes," "estimates," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences' control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences' filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

<u>**Contacts:**</u>

**Investors:**

Pulse Biosciences, Inc.

Jon Skinner, CFO

IR@pulsebiosciences.com

**Or**

<br> Gilmartin Group<br> Philip Trip Taylor

415.937.5406<br> philip@gilmartinir.com

------

**PULSE BIOSCIENCES, INC.**

**Condensed Consolidated Balance Sheets**

**(In thousands, except per share amounts)**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **September 30,** | **December 31,** |
|  | **2025** | **2024** |
| **ASSETS** |  |  |
| Current assets: |  |  |
| Cash and cash equivalents | $95214 | $118038 |
| &nbsp;&nbsp;&nbsp; Accounts Receivable | 15 |  |
| Inventory | 57 |  |
| Prepaid expenses and other current assets | 1871 | 1411 |
| Total current assets | 97157 | 119449 |
| Property and equipment, net | 1055 | 1160 |
| Intangible assets, net | 741 | 1220 |
| Goodwill | 2791 | 2791 |
| Right-of-use assets | 6316 | 7163 |
| Other assets | 705 | 677 |
| Total assets | $108765 | $132460 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| Accounts payable | $2978 | $1673 |
| Accrued expenses | 5203 | 7027 |
| Lease liability, current | 1519 | 1355 |
| Total current liabilities | 9700 | 10055 |
| Lease liability, less current | 6371 | 7543 |
| Total liabilities | 16071 | 17598 |
| Stockholders' equity: |  |  |
| Preferred stock, $0.001 par value; authorized – 50,000 shares; no shares issued and outstanding |  |  |
| Common stock, $0.001 par value: authorized – 500,000 shares; issued and outstanding – 67,738 shares and 65,926 shares as of September 30, 2025 and December 31, 2024, respectively | 68 | 66 |
| Additional paid-in capital | 538474 | 505296 |
| Accumulated deficit | (445848) | (390500) |
| Total stockholders' equity | 92694 | 114862 |
| Total liabilities and stockholders' equity | $108765 | $132460 |

---

------

**PULSE BIOSCIENCES, INC.**

**Condensed Consolidated Statements of Operations and Comprehensive Loss**

**(In thousands, except per share amounts)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue: |  |  |  |  |
| Product revenue | $86 | $— | $86 | $— |
| Cost and expenses: |  |  |  |  |
| Cost of product revenue | 279 |  | 279 |  |
| &nbsp;&nbsp;&nbsp; Research and development | 11393 | 7703 | 33794 | 21674 |
| &nbsp;&nbsp;&nbsp; Selling, general and administrative | 8781 | 5952 | 24699 | 14322 |
| Total cost and expenses | 20453 | 13655 | 58772 | 35996 |
| Loss from operations | (20367) | (13655) | (58686) | (35996) |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Interest income | 1001 | 976 | 3385 | 1804 |
| &nbsp;&nbsp;&nbsp; Other expense | (19) | (1) | (47) | (8) |
| Total other income | 982 | 975 | 3338 | 1796 |
| Net loss | (19385) | (12680) | (55348) | (34200) |
| Comprehensive loss | $(19385) | $(12680) | $(55348) | $(34200) |
| Net loss per share, basic and diluted | $(0.29) | $(0.21) | $(0.82) | $(0.60) |
| Weighted average common shares outstanding, basic and diluted | 67385 | 61066 | 67263 | 57169 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
| **Stock Based Compensation Expense:** | **2025** | **2024** | **2025** | **2024** |
| Cost of product revenue | $52 | $— | $52 | $— |
| Research and development | 2232 | 1108 | 7329 | 3058 |
| Selling, general and administrative | 3333 | 1874 | 9106 | 3735 |
| Total stock-based compensation expense | $5617 | $2982 | $16487 | $6793 |

---

------

**Reconciliation of GAAP to Non-GAAP Financial Measures**

**The following table presents the reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures:**

**(In thousands)**

**(Unaudited)**<br>

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended** | **Three Months Ended** | **Nine Months Ended** | **Nine Months Ended** |
|  | **September 30,** | **September 30,** | **September 30,** | **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Reconciliation of GAAP to non-GAAP Cost of product revenue:** |  |  |  |  |
| GAAP Cost of product revenue | $279 | $— | $279 | $— |
| Less: Stock-based compensation expense | (52) |  | (52) |  |
| Less: Depreciation and amortization | (3) |  | (3) |  |
| Non-GAAP Cost of product revenue | $224 | $— | $224 | $— |
| **Reconciliation of GAAP to non-GAAP Research and development:** |  |  |  |  |
| GAAP Research and development | $11393 | $7703 | $33794 | $21674 |
| Less: Stock-based compensation expense | (2232) | (1108) | (7329) | (3058) |
| Less: Depreciation and amortization | (41) | (47) | (131) | (152) |
| Non-GAAP Research and development | $9120 | $6548 | $26334 | $18464 |
| **Reconciliation of GAAP to non-GAAP Selling, general and administrative:** |  |  |  |  |
| GAAP Selling, general and administrative | $8781 | $5952 | $24699 | $14322 |
| Less: Stock-based compensation expense | (3333) | (1874) | (9106) | (3735) |
| Less: Depreciation and amortization | (212) | (247) | (678) | (739) |
| Add: Legal settlement |  |  | 590 |  |
| Non-GAAP Selling, general and administrative | $5236 | $3831 | $15505 | $9848 |
| **Reconciliation of GAAP to non-GAAP Cost and expenses:** |  |  |  |  |
| GAAP Cost and expenses | $20453 | $13655 | $58772 | $35996 |
| &nbsp;&nbsp;&nbsp; Less: Stock-based compensation expense | (5617) | (2982) | (16487) | (6793) |
| &nbsp;&nbsp;&nbsp; Less: Depreciation and amortization | (256) | (294) | (812) | (891) |
| Add: Legal settlement |  |  | 590 |  |
| Non-GAAP Cost and expenses | $14580 | $10379 | $42063 | $28312 |
| **Reconciliation of GAAP to non-GAAP Net loss:** |  |  |  |  |
| GAAP Net loss | $(19385) | $(12680) | $(55348) | $(34200) |
| Add: Stock-based compensation expense | 5617 | 2982 | 16487 | 6793 |
| Add: Depreciation and amortization | 256 | 294 | 812 | 891 |
| Less: Legal settlement |  |  | (590) |  |
| Non-GAAP Net loss | $(13512) | $(9404) | $(38639) | $(26516) |

---